Clinical trial · Interventional
Evaluating the Usefulness of 18F-AlF-FAPI PET/ CT in Orbital Neoplasms
Evaluating the Potential Usefulness of 18F-AlF-FAPI PET/ CT in Patients With Orbital Neoplasms and Compared With 18F-FDG PET/ CT
NCT06791226CI-TRIAL-00085059recruitingN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To evaluate the potential usefulness of 18F-AlF-FAPI positron emission tomography/computed tomography (PET/CT) for the diagnosis of primary and metastatic lesions in orbital neoplasms, and compared with 18F-FDG PET/CT.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Orbital Neoplasms | Orbital Neoplasm | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| 18F-AlF-FAPI PET/CT, 18F-FDG PET/CT | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Experimental arm
- description
- Experimental arm
- interventionNames
- Diagnostic Test: 18F-AlF-FAPI PET/CT, 18F-FDG PET/CT
Primary outcomes (1)
- measure
- Diagnostic accuracy
- timeFrame
- through study completion, an average of 6 months
- description
- The diagnostic accuracy of 18F-FDG and 18F-AlF-FAPI PET/CT were calculated and compared to evaluate the diagnostic efficacy.
Secondary outcomes (3)
- measure
- SUV metrics
- timeFrame
- through study completion, an average of 6 months
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 3 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: 1. patients with suspected or newly diagnosed orbital neoplasms (supporting evidence may include MRI, CT and pathology report); 2. patients who had scheduled both 18F-FDG and 18F-AlF-FAPI PET/CT scans; 3. patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee. Exclusion Criteria: 1. patients with pregnancy; 2. breastfeeding; 3. the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.
References
Publications (0)
Data not yet available
No reference posted for this study.